Vaccine candidates against hantavirus remain in early-stage development as of mid-2026, with no candidates having advanced to Phase 3 efficacy trials that could support regulatory approval before year-end. Recent outbreaks, including a cruise ship cluster, have accelerated preclinical work on DNA, mRNA, and subunit platforms targeting the Gn-Gc glycoproteins, yet these efforts are still generating neutralizing antibody data in animal models or small Phase 1/2 human studies. Standard clinical and regulatory timelines make licensure by December 2026 highly improbable absent unprecedented acceleration. Market-implied odds reflect this pipeline gap while leaving room for surprise breakthroughs if an emergency-use pathway opens or existing South Korean Hantavax expands broadly.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% шанс
$129,605 Обс.
$129,605 Обс.
Dec 31, 2026
6% шанс
$129,605 Обс.
$129,605 Обс.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates against hantavirus remain in early-stage development as of mid-2026, with no candidates having advanced to Phase 3 efficacy trials that could support regulatory approval before year-end. Recent outbreaks, including a cruise ship cluster, have accelerated preclinical work on DNA, mRNA, and subunit platforms targeting the Gn-Gc glycoproteins, yet these efforts are still generating neutralizing antibody data in animal models or small Phase 1/2 human studies. Standard clinical and regulatory timelines make licensure by December 2026 highly improbable absent unprecedented acceleration. Market-implied odds reflect this pipeline gap while leaving room for surprise breakthroughs if an emergency-use pathway opens or existing South Korean Hantavax expands broadly.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Ринок відкрито: May 4, 2026, 10:39 AM ET
Обсяг
$129,605Дата завершення
Dec 31, 2026Ринок відкрито
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates against hantavirus remain in early-stage development as of mid-2026, with no candidates having advanced to Phase 3 efficacy trials that could support regulatory approval before year-end. Recent outbreaks, including a cruise ship cluster, have accelerated preclinical work on DNA, mRNA, and subunit platforms targeting the Gn-Gc glycoproteins, yet these efforts are still generating neutralizing antibody data in animal models or small Phase 1/2 human studies. Standard clinical and regulatory timelines make licensure by December 2026 highly improbable absent unprecedented acceleration. Market-implied odds reflect this pipeline gap while leaving room for surprise breakthroughs if an emergency-use pathway opens or existing South Korean Hantavax expands broadly.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Обсяг
$129,605Дата завершення
Dec 31, 2026Ринок відкрито
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Vaccine candidates against hantavirus remain in early-stage development as of mid-2026, with no candidates having advanced to Phase 3 efficacy trials that could support regulatory approval before year-end. Recent outbreaks, including a cruise ship cluster, have accelerated preclinical work on DNA, mRNA, and subunit platforms targeting the Gn-Gc glycoproteins, yet these efforts are still generating neutralizing antibody data in animal models or small Phase 1/2 human studies. Standard clinical and regulatory timelines make licensure by December 2026 highly improbable absent unprecedented acceleration. Market-implied odds reflect this pipeline gap while leaving room for surprise breakthroughs if an emergency-use pathway opens or existing South Korean Hantavax expands broadly.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання